v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Collaboration and other research and development revenues $ 2,831 $ 4,658
Operating expenses:    
Research and development 17,600 26,593
General and administrative 10,234 13,375
Restructuring and impairment charges 0 40,853
Total operating expenses 27,834 80,821
Operating loss (25,003) (76,163)
Other income, net:    
Interest expense related to sale of future revenues (1,072) (2,216)
Interest income, net 1,206 2,716
Other expense, net (113) (425)
Total other income, net 21 75
Net loss $ (24,982) $ (76,088)
Net loss per share, basic (in dollars per share) $ (0.26) $ (0.92)
Net loss per share, diluted (in dollars per share) $ (0.26) $ (0.92)
Weighted-average common shares outstanding, basic (in shares) 97,879,343 83,055,066
Weighted-average common shares outstanding, diluted (in shares) 97,879,343 83,055,066